within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BX02_EbolaVaccines;

model EbolaVaccines
  extends Pharmacolibrary.Drugs.ATC.J.J07BX02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J07BX02</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ebola vaccines, classified under ATC code J07BX02, are vaccines developed to prevent Ebola virus disease. They are used for immunization against infection caused by Ebola virus species, particularly during outbreaks and for individuals at high risk, such as healthcare workers. Some Ebola vaccines, such as rVSV-ZEBOV (Ervebo), have been approved for use in certain countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters (such as absorption rate, clearance, or volume of distribution) have been reported for Ebola vaccines in humans. Vaccines generally act through immunogenicity rather than characteristic small-molecule pharmacokinetics. The available data concern immunogenic profiles rather than classical PK.</p><h4>References</h4><ol><li><p>Marquez-Martinez, S, et al., &amp; Khan, S (2024). Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses. <i>PloS one</i> 19(4) e0299215–None. DOI:<a href=\"https://doi.org/10.1371/journal.pone.0299215\">10.1371/journal.pone.0299215</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38626093/\">https://pubmed.ncbi.nlm.nih.gov/38626093</a></p></li><li><p>Sheets, RL, et al., &amp; Gomez, PL (2006). Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. <i>Toxicological sciences : an official journal of the Society of Toxicology</i> 91(2) 620–630. DOI:<a href=\"https://doi.org/10.1093/toxsci/kfj170\">10.1093/toxsci/kfj170</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16569728/\">https://pubmed.ncbi.nlm.nih.gov/16569728</a></p></li><li><p>Sheets, RL, et al., &amp; Gomez, P (2008). Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer&#x27;s construct, or gene inserts. <i>Journal of immunotoxicology</i> 5(3) 315–335. DOI:<a href=\"https://doi.org/10.1080/15376510802312464\">10.1080/15376510802312464</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18830892/\">https://pubmed.ncbi.nlm.nih.gov/18830892</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end EbolaVaccines;
